Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Jan 19, 2018
Clinical News

FDA approves AZ's Lynparza for breast cancer

BioCentury | Jul 25, 2017
Distillery Therapeutics

Cancer

BioCentury | Jun 17, 2017
Product Development

I-SPY adapts

Veliparib data provide lessons on combos in platform trials like I-SPY-2
BioCentury | May 18, 2017
Clinical News

Keytruda graduates from I-SPY 2

BioCentury | Apr 21, 2017
Clinical News

Veliparib: Ph III data

BioCentury | Apr 21, 2017
Clinical News

Veliparib: Ph III data

BioCentury | Apr 19, 2017
Clinical News

AbbVie's PARP fails in Phase III NSCLC, TNBC trials

Items per page:
1 - 10 of 44